By detecting 1,592 endothelial cells in lung cancer, Lambrechts et al. (2018) revealed that TECs downregulate immune attraction pathways by reducing the expression of chemotaxis (CCL2, CCL18, and IL6), adhesion molecules (ICAM1) and antigen presentation associated molecular (major histocompatibility complex class I and II), which contributes to tumor immunotolerance in TME. Here, CCL2 is linked to neoplasm.